Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 18/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 12/20 | 0.76 |
| ▸ | F9 | P00740 | 8/20 | 0.76 |
| ▸ | F12 | P00748 | 1/20 | 0.72 |
| ▸ | PLAT | P00750 | 1/20 | 0.72 |
| ▸ | PROC | P04070 | 1/20 | 0.72 |
| ▸ | F7 | P08709 | 1/20 | 0.72 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.72 |
| ▸ | CTRL | P40313 | 1/20 | 0.72 |
| ▸ | CTRB2 | Q6GPI1 | 1/20 | 0.72 |
| ▸ | CTRC | Q99895 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20879187 | 0.99 | F11 (0.97) | F11KLKB1F9F12PLAT | |
| SCHEMBL14700910 | 0.91 | F11 (1.00) | F11KLKB1F9F12PLAT | |
| SCHEMBL14700969 | 0.90 | F11 (0.82) | F11KLKB1F9F12PLAT | |
| SCHEMBL14700936 | 0.89 | F11 (1.00) | F11KLKB1F9F12PLAT | |
| SCHEMBL20879307 | 0.86 | F11 (1.00) | F11KLKB1F9F12PLAT | |
| SCHEMBL14700818 | 0.86 | F11 (1.00) | F11KLKB1F9F12PLAT | |
| SCHEMBL15594227 | 0.86 | F11 (1.00) | F11KLKB1F9F12PLAT | |
| SCHEMBL20879224 | 0.85 | F11 (1.00) | F11KLKB1F9F12PLAT | |
| SCHEMBL20879149 | 0.85 | F11 (1.00) | F11KLKB1F9F12PLAT | |
| SCHEMBL14700844 | 0.85 | F11 (1.00) | F11KLKB1F9F12PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070087-B1 | INTERMEDIATES FOR THE SYNTHESIS OF CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3070087-B1 | INTERMEDIATES FOR THE SYNTHESIS OF CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3070087-A1 | INTERMEDIATES FOR THE SYNTHESIS OF CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-3070087-A1 | INTERMEDIATES FOR THE SYNTHESIS OF CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2739625-B1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2739625-B1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9108981-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108981-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150057262-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2015-02-26 | — | — | US | disclosed |
| US-20150057262-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2015-02-26 | — | — | US | disclosed |
| US-8901115-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901115-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2013022814-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057262-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | F11, F12, F13A1 | F11 1/4885KLKB1 10/4885F9 13/4885 |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | F11, F12, F13A1 | F11 1/4885KLKB1 10/4885F9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.